He contraceptive Marilow has been withdrawn from the market by the Institute of Public Health (ISP) due to a decrease in the potency of its active ingredients. The Recalcine laboratory, manufacturer of the drug, took the measure voluntarily and affects all current batches of the product. Failure of the drug specifications was identified by the laboratory during stability studies routinely performed to verify the quality of the products.
Faced with this situation, the ISP has recommended that people refrain from using the Marilow contraceptive and replace it with another of similar composition. It is important to consult with a doctor before switching to another contraceptive medication for proper advice.
The withdrawal of a contraceptive of the market is a security measure to protect the health of users. The ISP is responsible for ensuring the quality and efficacy of the pharmaceutical products available in the country. In this case, the detection of decreased potency of the Marilow contraceptive during stability studies was reason enough for its withdrawal.
It is essential that people are informed about this recall and follow the recommendations of the ISP. Sexual and reproductive health is an important issue and having reliable contraceptive methods is essential to avoid unwanted pregnancies and protect people’s health. If you have been using the Marilow contraceptive, it is important that you consult a doctor to receive instructions on how to proceed and what alternatives you can consider.
The withdrawal of a drug from the market is a measure taken with the aim of guaranteeing the safety and efficacy of pharmaceutical products. In this case, the contraceptive Marilow has been withdrawn due to a decrease in the potency of its active ingredients detected by the manufacturer’s laboratory. If you are using this contraceptive, it is recommended that you refrain from continuing to use it and consult a doctor to discuss replacement options.
